Bli medlem
Bli medlem

Du är här

2021-05-27

PEPTONIC Medical AB: Communique from annual general meeting in PEPTONIC medical AB (publ)

The annual general meeting in PEPTONIC medical AB (publ), corp. reg. no 556776-3064 (the "Company") was held on 27 May 2021 by postal voting whereby the shareholders primarily resolved on the following matters.

Annual report and results

The annual general meeting adopted the income statement and the balance sheet for the financial year 2020 and resolved, in accordance with the board of directors' proposal, that the result according to the approved income statement should be transferred to a new account. No dividends are to be paid.

Discharge from liability

The general meeting granted the members of the board of directors and the managing director discharge from liability for the management of the Company's business for the financial year 2020.

Remuneration to the board of directors and the auditor and numb

The annual general meeting resolved that the chairman shall receive remuneration with SEK 150,000 and that every other board member shall receive remuneration with SEK 75,000.

The annual general meeting resolved that the auditor shall receive remuneration according to approved invoice.

Election of board of directors and auditor

The annual general meeting resolved that the board of directors shall consist of four (4) directors without any deputy directors.

The general meeting resolved, for the time until the end of the next annual general meeting, to re-elect Hans von Celsing, Anna Tenstam, Marianne Östlund and Leni Ekendahl as members of the board of directors. Hans von Celsing was elected as the chairman of the board of directors.

It was resolved to re-elect KPMG AB as auditor, with Emil Andersson as chief auditor, for the time until the end of the next annual general meeting.

Authorization to the board of directors to resolve on new issues

The annual general meeting authorized the board of directors, for the time until the next annual general meeting, whether on one or several occasions, to increase the Company's share capital with an amount that corresponds to twenty (20) percent of the Company's registered share capital at the time of the first utilisation of the authorisation. The board of directors shall be entitled to resolve on issues of shares, warrants and/or convertible instruments with or without deviation from the shareholders' pre-emption rights and/or by an issue in kind or by way of set-off. An issue in accordance with this authorisation shall be on market conditions.

The resolution was supported by shareholders holding more than two thirds of the votes cast and the shares represented at the general meeting.

Nomination committee for the annual general meeting 2022

The annual general meeting resolved that the Company, in advance of the annual general meeting in 2022, shall establish a nomination committee. It was resolved that the members of the nomination committee shall be appointed by instruction from the chairman of the board of directors to the three largest shareholders in the Company on 1 September 2021 to appoint a representative each that, together with the chairman of the board of directors, shall constitute the nomination committee.

Erik Sundquist, CEO

Telefon: + 46 722 49 90 43

E-post: erik.sundquist@peptonicmedical.se

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.